Literature DB >> 29185711

Discovery and Biological Evaluation of Potent and Selective N-Methylene Saccharin-Derived Inhibitors for Rhomboid Intramembrane Proteases.

Parul Goel1,2, Thorsten Jumpertz1, David C Mikles3, Anežka Tichá3, Minh T N Nguyen4, Steven Verhelst4,5, Martin Hubalek3, Darren C Johnson6, Daniel A Bachovchin6, Isabella Ogorek1, Claus U Pietrzik7, Kvido Strisovsky3, Boris Schmidt2, Sascha Weggen1.   

Abstract

Rhomboids are intramembrane serine proteases and belong to the group of structurally and biochemically most comprehensively characterized membrane proteins. They are highly conserved and ubiquitously distributed in all kingdoms of life and function in a wide range of biological processes, including epidermal growth factor signaling, mitochondrial dynamics, and apoptosis. Importantly, rhomboids have been associated with multiple diseases, including Parkinson's disease, type 2 diabetes, and malaria. However, despite a thorough understanding of many structural and functional aspects of rhomboids, potent and selective inhibitors of these intramembrane proteases are still not available. In this study, we describe the computer-based rational design, chemical synthesis, and biological evaluation of novel N-methylene saccharin-based rhomboid protease inhibitors. Saccharin inhibitors displayed inhibitory potency in the submicromolar range, effectiveness against rhomboids both in vitro and in live Escherichia coli cells, and substantially improved selectivity against human serine hydrolases compared to those of previously known rhomboid inhibitors. Consequently, N-methylene saccharins are promising new templates for the development of rhomboid inhibitors, providing novel tools for probing rhomboid functions in physiology and disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29185711      PMCID: PMC6040592          DOI: 10.1021/acs.biochem.7b01066

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  56 in total

Review 1.  Strategies for the inhibition of serine proteases.

Authors:  B Walker; J F Lynas
Journal:  Cell Mol Life Sci       Date:  2001-04       Impact factor: 9.261

2.  Crystal structure of a rhomboid family intramembrane protease.

Authors:  Yongcheng Wang; Yingjiu Zhang; Ya Ha
Journal:  Nature       Date:  2006-10-11       Impact factor: 49.962

Review 3.  Rhomboid protease inhibitors: Emerging tools and future therapeutics.

Authors:  Kvido Strisovsky
Journal:  Semin Cell Dev Biol       Date:  2016-08-24       Impact factor: 7.727

4.  Catalytic mechanism of rhomboid protease GlpG probed by 3,4-dichloroisocoumarin and diisopropyl fluorophosphonate.

Authors:  Yi Xue; Ya Ha
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

Review 5.  Recent developments in the design of mechanism-based and alternate substrate inhibitors of serine proteases.

Authors:  Jiaying Zhong; William C Groutas
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

6.  Crystal Structures and Inhibition Kinetics Reveal a Two-Stage Catalytic Mechanism with Drug Design Implications for Rhomboid Proteolysis.

Authors:  Sangwoo Cho; Seth W Dickey; Siniša Urban
Journal:  Mol Cell       Date:  2016-01-21       Impact factor: 17.970

7.  Inhibition of elastase and other serine proteases by heterocyclic acylating agents.

Authors:  M Zimmerman; H Morman; D Mulvey; H Jones; R Frankshun; B M Ashe
Journal:  J Biol Chem       Date:  1980-10-25       Impact factor: 5.157

Review 8.  Mechanism-based isocoumarin inhibitors for serine proteases: use of active site structure and substrate specificity in inhibitor design.

Authors:  J C Powers; C M Kam; L Narasimhan; J Oleksyszyn; M A Hernandez; T Ueda
Journal:  J Cell Biochem       Date:  1989-01       Impact factor: 4.429

9.  Mammalian EGF receptor activation by the rhomboid protease RHBDL2.

Authors:  Colin Adrain; Kvido Strisovsky; Markus Zettl; Landian Hu; Marius K Lemberg; Matthew Freeman
Journal:  EMBO Rep       Date:  2011-04-15       Impact factor: 8.807

10.  Monocyclic β-lactams are selective, mechanism-based inhibitors of rhomboid intramembrane proteases.

Authors:  Olivier A Pierrat; Kvido Strisovsky; Yonka Christova; Jonathan Large; Keith Ansell; Nathalie Bouloc; Ela Smiljanic; Matthew Freeman
Journal:  ACS Chem Biol       Date:  2011-01-12       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.